JP2013533259A5 - - Google Patents

Download PDF

Info

Publication number
JP2013533259A5
JP2013533259A5 JP2013518810A JP2013518810A JP2013533259A5 JP 2013533259 A5 JP2013533259 A5 JP 2013533259A5 JP 2013518810 A JP2013518810 A JP 2013518810A JP 2013518810 A JP2013518810 A JP 2013518810A JP 2013533259 A5 JP2013533259 A5 JP 2013533259A5
Authority
JP
Japan
Prior art keywords
composition
lipid
composition according
antigen
influenza virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013518810A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013533259A (ja
JP6119030B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/043094 external-priority patent/WO2012006367A2/en
Publication of JP2013533259A publication Critical patent/JP2013533259A/ja
Publication of JP2013533259A5 publication Critical patent/JP2013533259A5/ja
Application granted granted Critical
Publication of JP6119030B2 publication Critical patent/JP6119030B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013518810A 2010-07-06 2011-07-06 インフルエンザを治療するための組成物及び方法 Expired - Fee Related JP6119030B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36189810P 2010-07-06 2010-07-06
US61/361,898 2010-07-06
US201161431218P 2011-01-10 2011-01-10
US61/431,218 2011-01-10
PCT/US2011/043094 WO2012006367A2 (en) 2010-07-06 2011-07-06 Compositions and methods for treating influenza

Publications (3)

Publication Number Publication Date
JP2013533259A JP2013533259A (ja) 2013-08-22
JP2013533259A5 true JP2013533259A5 (cg-RX-API-DMAC7.html) 2014-08-21
JP6119030B2 JP6119030B2 (ja) 2017-04-26

Family

ID=45441781

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518810A Expired - Fee Related JP6119030B2 (ja) 2010-07-06 2011-07-06 インフルエンザを治療するための組成物及び方法

Country Status (10)

Country Link
US (1) US9610248B2 (cg-RX-API-DMAC7.html)
EP (1) EP2590674B1 (cg-RX-API-DMAC7.html)
JP (1) JP6119030B2 (cg-RX-API-DMAC7.html)
CN (1) CN103096922B (cg-RX-API-DMAC7.html)
AU (1) AU2011276223C1 (cg-RX-API-DMAC7.html)
BR (1) BR112013000394B8 (cg-RX-API-DMAC7.html)
CA (1) CA2840079C (cg-RX-API-DMAC7.html)
IL (1) IL224022B (cg-RX-API-DMAC7.html)
MX (1) MX342138B (cg-RX-API-DMAC7.html)
WO (1) WO2012006367A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
CA2767392C (en) * 2009-07-06 2017-03-14 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
CN103501811B (zh) * 2011-01-13 2016-03-30 变异生物技术公司 用于治疗病毒感染的组合物和方法
WO2013072768A2 (en) * 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Synthetic derivatives of mpl and uses thereof
EP2802353A4 (en) * 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
EP2806894A4 (en) 2012-01-27 2015-11-04 Variation Biotechnologies Inc METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENTS
US9149521B2 (en) * 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) * 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
GB201814959D0 (en) * 2018-09-14 2018-10-31 Secr Defence Methods for the preparation of a pharmaceutical-vesicle formulation and associated products and uses

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024241A (en) 1974-09-27 1977-05-17 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US3952097A (en) 1974-09-27 1976-04-20 The United States Of America As Represented By The Department Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US4349538A (en) 1979-12-07 1982-09-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
JPS56115727A (en) 1980-02-19 1981-09-11 Kuraray Co Ltd Carrier for immobilizing physiologically active substance
US4537769A (en) * 1982-04-06 1985-08-27 American Cyanamid Company Stabilization of influenza virus vaccine
US4894228A (en) 1982-04-07 1990-01-16 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against hepatitis A virus
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4983387A (en) 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
ATE71292T1 (de) 1987-03-13 1992-01-15 Micro Vesicular Systems Lipidversikel aus grenzflaechenaktiven stoffen und sterolen.
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5160669A (en) 1988-03-03 1992-11-03 Micro Vesicular Systems, Inc. Method of making oil filled paucilamellar lipid vesicles
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US4911517A (en) 1988-09-09 1990-03-27 Square D Company Means for clamping fiber optical cable
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5817318A (en) 1989-05-03 1998-10-06 Connaught Laboratories Limited Synthetic peptides for an HIV-1 vaccine
CN1022331C (zh) 1989-08-17 1993-10-06 浙江省医学科学院 甲型肝炎减毒活疫苗毒种及其制造方法
DE3934366A1 (de) 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
IE904098A1 (en) 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
ES2138588T3 (es) * 1990-06-29 2000-01-16 Chiron Corp Composiciones de vacunas que contienen liposomas.
US5250236A (en) 1991-08-05 1993-10-05 Gasco Maria R Method for producing solid lipid microspheres having a narrow size distribution
GB9207731D0 (en) 1992-04-07 1992-05-27 Proteus Molecular Design Improvements in or relating to vaccines
ES2107668T3 (es) 1992-07-08 1997-12-01 Dianorm G Maierhofer Gmbh Liposomas, procedimiento para su preparacion y su uso en la elaboracion de un medicamento.
EP0666751B1 (en) 1992-09-18 2001-09-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Mutants of hepatitis a virus strain hm-175 for use as hepatitis a vaccines
US5393527A (en) 1993-01-04 1995-02-28 Becton, Dickinson And Company Stabilized microspheres and methods of preparation
JPH08507077A (ja) 1993-02-26 1996-07-30 ファウンティン、ファーマスーティカルズ、インク ワクチン送達系、および活性成分の遠隔封入のための保存安定性前駆溶液
US5885486A (en) 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
CA2163860A1 (en) 1993-06-30 1995-01-12 Chung C. Hsu Method for preparing liposomes
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
GB9320597D0 (en) 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
WO1995014026A1 (en) 1993-11-17 1995-05-26 Laboratoires Om S.A. Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CA2180965C (en) 1994-01-11 2010-05-11 Tom Maria Deroo Influenza vaccine
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US6235888B1 (en) 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
GB9515868D0 (en) 1995-08-02 1995-10-04 Proteus Molecular Design Therapeutic method
GB9522351D0 (en) 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
US5700679A (en) 1996-06-07 1997-12-23 Novavax, Inc. Lipid vesicles having a bilayer containing a surfactant with anti-viral and spermicidal activity
US5919480A (en) * 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
CA2259520C (en) 1996-07-03 2007-09-11 Eisai Co., Ltd. Preparation for injection containing a lipid a analog and process for preparing the same
ZA975889B (en) 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
KR100507660B1 (ko) 1996-09-13 2005-08-10 리폭센 테크놀로지즈 리미티드 리포좀
US5910306A (en) 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US6290967B1 (en) 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
FR2760367B1 (fr) 1997-03-06 1999-04-30 Pasteur Merieux Serums Vacc Composition vaccinale destinee a la prevention ou au traitement des hepatites c
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
EP0996451B1 (en) 1997-05-20 2005-01-05 Galenica Pharmaceuticals, Inc. Triterpene saponin analogs having adjuvant and immunostimulatory activity
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
US6503753B1 (en) 1998-02-13 2003-01-07 Adan Rios Method for the development of an HIV vaccine
AU764938B2 (en) 1998-02-13 2003-09-04 Adan Rios Method for the development of an HIV vaccine
US6500623B1 (en) 1998-05-12 2002-12-31 Genecure Llp Replication defective HIV vaccine
US7067134B1 (en) 1998-08-12 2006-06-27 University Of Western Ontario HIV vaccine
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
GB9822714D0 (en) 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
US6287570B1 (en) 1998-11-23 2001-09-11 Patricia L. Foley Vaccine against swine influenza virus
GB9826069D0 (en) 1998-11-28 1999-01-20 Univ Leeds HIV vaccine
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
NO311807B1 (no) 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
JP2003530307A (ja) 1999-07-06 2003-10-14 メルク・アンド・カンパニー・インコーポレーテッド ｇａｇ遺伝子保有アデノウイルスＨＩＶワクチン
AU5905400A (en) 1999-07-14 2001-02-05 Board Of Regents, The University Of Texas System Methods and compositions for delivery and retention of active agents to lymph nodes
AU769357B2 (en) 1999-07-15 2004-01-22 University Of British Columbia, The Methods for preparation of lipid-encapsulated therapeutic agents
US6541003B1 (en) 1999-07-28 2003-04-01 Infectious Diseases Foundation Conditionally controlled, attenuated HIV vaccine
DE60036952T2 (de) 1999-09-24 2008-08-07 Glaxosmithkline Biologicals S.A. Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
CA2400468C (en) 2000-02-15 2012-12-18 Intellivax International Inc. Proteosome influenza vaccine
FR2806912B1 (fr) 2000-04-04 2004-07-23 Fond Mondiale Rech Et Preventi UTILISATION DE PROTEINES gp120 ET gp160 MODIFIEES DANS LA BOUCLE V3 DU VIH-1 POUR LA PREPARATION DE COMPOSITIONS VACCINALES ET FORMULATIONS LES CONTENANT
US20030092145A1 (en) 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
JP5063852B2 (ja) 2000-09-25 2012-10-31 ポリマン サイエンティフィック イミューンバイオロジッシュ フォーシュング ゲゼルシャフト ミット ベシュレンクテル ファフツング 生ワクチン及び製造方法
US20040081688A1 (en) 2000-12-27 2004-04-29 Del Curto Maria Dorly Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
ATE458496T1 (de) 2002-01-14 2010-03-15 Novartis Vaccines & Diagnostic Hiv-vakzine und anwendungsverfahren
US7285289B2 (en) 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
US20050169979A1 (en) 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
RU2311911C2 (ru) 2002-07-05 2007-12-10 Липоксен Текнолоджиз Лимитед Способ усиления иммунного ответа при вакцинации нуклеиновой кислотой
US20040011840A1 (en) 2002-07-22 2004-01-22 Lovett Terry E. Rolling motorcycle bag
KR101251902B1 (ko) 2003-02-25 2013-04-08 메디뮨 엘엘씨 인플루엔자 백신 조성물의 제조 방법
NZ543467A (en) 2003-04-10 2008-07-31 Novartis Vaccines & Diagnostic The severe acute respiratory syndrome coronavirus
EP1623015A4 (en) 2003-05-15 2007-10-10 Univ Oklahoma State HA1 OF THE EQUINE-2 INFLUENZAVIRUS EXPRESSIVE DNA VACCINE
EP1638919B1 (en) 2003-06-18 2012-09-26 Biolab Ltd. Sphingolipids polyalkylamines conjugates
US7368537B2 (en) 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
US20050095283A1 (en) 2003-09-16 2005-05-05 Aphios Corporation Compositions and methods for topically treating diseases
US20080160089A1 (en) 2003-10-14 2008-07-03 Medivas, Llc Vaccine delivery compositions and methods of use
US7498309B2 (en) 2003-11-29 2009-03-03 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
EP2530147B1 (en) 2004-05-25 2014-09-10 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
DE602005025342D1 (de) 2004-05-28 2011-01-27 Glaxosmithkline Biolog Sa Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
AU2005295072A1 (en) 2004-10-08 2006-04-20 Alza Corporation Method of insertion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves
US7510719B2 (en) 2004-12-08 2009-03-31 Medimmune, Llc Methods of producing influenza vaccine compositions
EP1676569A1 (en) 2004-12-30 2006-07-05 Pevion Biotech Ltd. Lyophilization of virosomes
WO2006092046A1 (en) 2005-03-01 2006-09-08 Variation Biotechnologies Inc. Hiv vaccine composition
US20090028903A1 (en) 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
US7348011B2 (en) 2005-06-10 2008-03-25 Sudershan Biotech Ltd. Hepatitis C virus vaccine
WO2006138719A2 (en) 2005-06-17 2006-12-28 Georgia Tech Research Corporation Coated microstructures and method of manufacture thereof
EP2883957A1 (en) 2005-11-25 2015-06-17 Zoetis Belgium S.A. Immunostimmulatory oligoribonucleotides
EP1979488A4 (en) 2006-01-09 2009-05-27 Univ California IMMUNOSTIMULATING COMBINATIONS OF TNFRSF, TLR, NLR, RHR, PURINERIC RECEPTOR, AND CYTOKIN RECEPTOR ANTONISTS FOR VACCINES AND TUMOR IMMUNOTHERAPY
WO2007098186A2 (en) 2006-02-22 2007-08-30 Novavax, Inc. Adjuvant and vaccine compositions
US8846078B2 (en) 2006-03-21 2014-09-30 The Secretary Of State For Environment, Food & Rural Affairs Acting Through The Animal Health And Veterinary Laboratories Agency Brucellosis DNA vaccine
WO2007110776A1 (en) * 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
WO2008082721A2 (en) 2006-09-05 2008-07-10 Medivas, Llc Polymer-stabilized liposomal compositions and methods of use
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
SI2468300T1 (en) * 2006-09-26 2018-03-30 Infectios Disease Research Institute A vaccine composition comprising a synthetic adjuvant
MX2009009530A (es) 2007-03-07 2010-05-19 Nventa Biopharmaceuticals Corp Composiciones de acidos nucleicos cerrados bicatenarios.
US11246831B2 (en) 2007-03-30 2022-02-15 Particle Sciences, Inc. Particle formulations and uses thereof
EP2014279A1 (en) * 2007-06-22 2009-01-14 Pevion Biotech AG Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof
SG10201404101RA (en) 2007-08-28 2014-09-26 Baxter Int Method For Producing Viral Vaccines
US20110105995A1 (en) * 2008-01-16 2011-05-05 Zhu Ting F Uniform-sized, multi-drug carrying, and photosensitive liposomes for advanced drug delivery
AU2009259964B2 (en) * 2008-06-19 2015-04-09 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
WO2010033812A1 (en) 2008-09-18 2010-03-25 Variation Biotechnologies, Inc. Compositions and methods for treating hepatitis a.
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
CA2767392C (en) 2009-07-06 2017-03-14 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
WO2012006368A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
AU2012205315B2 (en) 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CN103501811B (zh) 2011-01-13 2016-03-30 变异生物技术公司 用于治疗病毒感染的组合物和方法
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
EP2806894A4 (en) 2012-01-27 2015-11-04 Variation Biotechnologies Inc METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENTS

Similar Documents

Publication Publication Date Title
JP2013533259A5 (cg-RX-API-DMAC7.html)
HRP20190876T1 (hr) Novi adjuvantirani pripravci
Kreijtz et al. Immune responses to influenza virus infection
Rimmelzwaan et al. Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development
Bosch et al. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A (H1N1) influenza virus infection in ferrets
JP2012532200A5 (cg-RX-API-DMAC7.html)
PE20090146A1 (es) Composicion inmunogenica contra el virus influenza
Carascal et al. Recent progress in recombinant influenza vaccine development toward heterosubtypic immune response
JP2011504486A5 (cg-RX-API-DMAC7.html)
JP2013047265A5 (cg-RX-API-DMAC7.html)
BR112014004687A2 (pt) imidazopiridazinas amino-substituídas
JP2012511914A5 (cg-RX-API-DMAC7.html)
JP2013126989A5 (cg-RX-API-DMAC7.html)
WO2007124479A3 (en) Avian influenza viruses, vaccines, compositions, formulations, and methods
JP2013537518A5 (cg-RX-API-DMAC7.html)
JP2014532620A5 (cg-RX-API-DMAC7.html)
BR112013005679A2 (pt) imidazopiridazinas substituídas
BR112014011345A2 (pt) partículas tipo vírus da influenza (vlps) compreendendo nicotiana tabacum produzida por hemaglutinina
ZA202310755B (en) Immunogenic composition against influenza
HRP20241144T1 (hr) Stabilne formulacije lipida i lipozoma
BR112014017756A8 (pt) Sistema de administração transmucosa para um medicamento
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
NZ618158A (en) Compositions and methods for administration of vaccines against dengue virus
BR112015014174A2 (pt) composição de vacina para indivíduos virgens
WO2012075376A3 (en) Lyophilized viral formulations